Peptigrade

Metabolic & Longevity

MOTS-c

Mitochondrial Open Reading Frame of the 12S rRNA Type-c — 16-aa peptide MRWQEMGYIFYPRKLR·Also known as: MOTS-c, Mitochondrial-Derived Peptide MOTS-c, MT-RNR1 sORF peptide

FDARegulatory status

Not approved for human use. No FDA-approved indication exists. Sold in the United States solely as a research chemical for in-vitro and animal studies.

WADARegulatory status

Not explicitly named on the 2026 WADA Prohibited List (in force January 1, 2026). As a non-approved substance with pharmacological action on metabolism, it is captured by S0 (non-approved substances) at all times and by S4.5 (metabolic modulators) in the judgment of most anti-doping lawyers. Athletes should treat it as prohibited.

Regulatory note ·MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded by a short open reading frame within the mitochondrial 12S rRNA (MT-RNR1) gene. It was discovered and characterized by Lee et al. at USC and published in Cell Metabolism in 2015. As of 2026-04-20, there is no registered Phase 2 or Phase 3 trial of synthetic MOTS-c for any human outcome on ClinicalTrials.gov — the entire clinical dossier consists of observational human biomarker studies (Du 2018, Ramanjaneya 2019) and the exercise-induction human data embedded in Reynolds 2021. No major regulator (FDA, EMA, PMDA) has reviewed the compound for a therapeutic indication.

§ The quick take

TL;DR · Editor’s summary

MOTS-c is the best-characterized member of the mitochondrial-derived-peptide family and has a cleaner mechanistic paper trail than most investigational peptides: Lee 2015 (Cell Metabolism) identified it in the mitochondrial 12S rRNA sORF, demonstrated folate-cycle inhibition leading to >20-fold AICAR accumulation and AMPK-Thr172 phosphorylation, and showed prevention of high-fat-diet and age-dependent insulin resistance in mice. Kim 2018 (Cell Metabolism) added the stress-responsive nuclear-translocation arm, and Reynolds 2021 (Nature Communications) established the exercise-mimetic framing — endogenous muscle MOTS-c rose ~12-fold post-exercise in humans and late-life MOTS-c treatment roughly doubled treadmill capacity in aged mice with trends toward ~6–7% median and maximum lifespan extension. The evidence stops there.

The entire human dossier is observational biomarker work (Du 2018 and Ramanjaneya 2019 both show inverse associations between circulating MOTS-c and insulin resistance / BMI) plus the exercise-induction measurements in Reynolds. No interventional trial of exogenous synthetic MOTS-c in humans has been published or registered as of 2026-04-20; no Phase 2 or Phase 3 exists for any indication; no human pharmacokinetic or immunogenicity data has been reported in peer-reviewed literature. Under the Peptigrade rubric this is a C for the metabolic/AMPK mechanism (replicated animal efficacy, characterized pathway, human observational support) and D for every specific human outcome because no human dosing trial has been run.

It is not FDA-approved, and athletes should treat it as WADA-prohibited under S0 and S4.5 even though it is not named on the list. Long-term human safety, optimal dosing, and translation of the mouse survival trend are all unknown.

§ Grade matrix

The grade
per outcome.

One peptide can earn very different grades for different uses. Here is every outcome we’ve graded for MOTS-c, sorted by strength of evidence.

C

Insulin sensitivity & metabolic homeostasis

Mixed

Lee 2015 (Cell Metab) established that MOTS-c prevents high-fat-diet and age-dependent insulin resistance in mice via folate-AICAR-AMPK activation in skeletal muscle. Replicated mechanistically in multiple rodent and cell-culture labs. Human evidence is observational only (Du 2018 T2D cohort, Ramanjaneya 2019) — no interventional trial of exogenous MOTS-c in humans has been published.

14 studiesUpdated 2026-04-20
D

Physical performance & age-related physical decline

Weak

Reynolds 2021 (Nat Commun) showed late-life intermittent MOTS-c dosing in mice roughly doubled treadmill running capacity and improved healthspan, with trends toward ~6% median and ~7% maximum lifespan extension (n underpowered for survival). Human arm of the same paper is exercise-induction only (endogenous MOTS-c rises ~12-fold in muscle, ~50% in plasma post-exercise). No human dosing trial.

6 studiesUpdated 2026-04-20
D

Obesity & diet-induced weight gain

Weak

Lee 2015 and Reynolds 2021 both showed MOTS-c treatment attenuates high-fat-diet weight gain in mice, mediated by AMPK-ACC lipogenic suppression and increased fatty-acid oxidation. No human weight-loss trial. Human plasma MOTS-c is inversely associated with BMI in cross-sectional cohorts (Du 2018, Ramanjaneya 2019) — correlation, not causation.

7 studiesUpdated 2026-03-28
D

Type 2 diabetes & glucose homeostasis

Weak

Du 2018 (Diab Res Clin Pract) reported lower circulating MOTS-c in newly diagnosed T2D patients (n=107) vs controls; Ramanjaneya 2019 (J Clin Endocrinol Metab) found similar inverse associations with HOMA-IR in a UK cohort. These are observational biomarker studies, not interventional. No trial has given synthetic MOTS-c to diabetic humans.

9 studiesUpdated 2026-03-28
Ins.

Mitochondrial biogenesis & NAD+/SIRT1 axis

Insufficient

Cell-culture and mouse data (Kim 2018 Cell Metab) show MOTS-c increases NAD+ availability and SIRT1-dependent glycolytic gene expression, with nuclear translocation under metabolic stress. Mechanistically interesting but no human biomarker or functional data.

4 studiesUpdated 2026-02-18
Ins.

Acute lung injury / cardiopulmonary bypass

Insufficient

A single 2025 study in AJRCMB reported MOTS-c protects pulmonary vascular endothelial cells from bypass-induced injury via AMPK–HIF-1α–PFKFB3 glycolytic reprogramming in a rodent/cell model. One lab, preclinical only.

2 studiesUpdated 2026-01-10
D

Longevity / lifespan extension

Weak

Reynolds 2021 showed late-life MOTS-c trended toward 6.4% median and 7.0% maximum lifespan extension in mice (hazard ratio 0.654) — under-powered for survival statistics. Population-genetics signal from the m.1382A>C variant enriched in long-lived Japanese cohorts (Fuku 2015, Zempo 2016) is suggestive but not causal. No human longevity trial exists or is plausible in a reasonable timeframe.

5 studiesUpdated 2026-02-02

§ Why this grade

Sub-scores for this outcome.

Insulin sensitivity & metabolic homeostasis

Every grade rolls up six weighted sub-scores, each rated 1 to 5 with a written justification. Here is how the top-outcome grade was constructed.

Mechanism understood

4 / 5

Folate-AICAR-AMPK pathway characterized by Lee 2015 through unbiased metabolomics with direct measurement of folate-cycle intermediates, AICAR accumulation (>20-fold), and AMPK-Thr172 phosphorylation. Reversible by folate supplementation. Nuclear-translocation arm added by Kim 2018. No receptor identified; human PK absent. Holds the mechanism score back from a 5.

Human studies (count + quality)

2 / 5

Du 2018 (n=107 newly diagnosed T2D vs controls) and Ramanjaneya 2019 (UK cohort, HOMA-IR associations) are observational biomarker studies — they show endogenous MOTS-c tracks with metabolic health but do not test exogenous dosing. The exercise-induction measurements in Reynolds 2021 are mechanistic human data, not an efficacy trial. No interventional human trial exists.

Effect vs placebo

1 / 5

Zero placebo-controlled human dosing trials for any indication. Mouse studies consistently show effect vs vehicle for insulin sensitivity, weight, and performance endpoints. Mouse-vs-vehicle is not the same as human-vs-placebo under the rubric.

Long-term safety data

1 / 5

No human repeated-dose safety data exists. Longest reported human exposure is the endogenous exercise response (transient, physiologic). Mouse studies have run for months with no overt toxicity reported but have not been designed as formal toxicology.

Side effect profile

3 / 5

No adverse events have been published because no human dosing trial has been run. Mouse studies report the peptide as well tolerated. Theoretical concerns: chronic AMPK activation across non-target tissues, and unknown immunogenicity of a repeatedly dosed peptide with no human exposure history.

Regulatory status

1 / 5

Not FDA-approved. No EMA, PMDA, or other major-regulator review. Captured by WADA S0 (non-approved substances) and arguably S4.5 (metabolic modulators) at all times, though not named on the 2026 list. Research-only status worldwide.

§ What the science says

How MOTS-c
works.

Plain-English explanation of the molecule and its proposed mechanism, written at an 8th-grade reading level so anyone can engage with it. Every claim is linked to a primary source below.

What it is

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide with sequence MRWQEMGYIFYPRKLR (molecular weight 2,174.64 Da, CAS 1627580-64-6). It is encoded by a 51-base-pair short open reading frame (sORF) within the mitochondrial 12S ribosomal RNA (MT-RNR1) gene, rather than by nuclear DNA. This makes it one of the first identified mitochondrial-derived peptides (MDPs), alongside humanin and the SHLP 1–6 family, and the first known example of a hormone-like signaling molecule encoded directly by the mitochondrial genome. The peptide was discovered and characterized by Changhan Lee, Pinchas Cohen and colleagues at USC, with the primary publication in Cell Metabolism in 2015. The first 11 amino acid residues are conserved across 14 mammalian species, suggesting long evolutionary selective pressure on its signaling role.

How it works

  1. 01

    Folate-AICAR-AMPK pathway (primary mechanism)

    Lee 2015 (Cell Metab 21:443-454) characterized the primary pathway through unbiased metabolomic profiling of MOTS-c-treated cells. MOTS-c inhibits the folate-methionine cycle — 5-methyltetrahydrofolate and methionine drop while homocysteine rises — which blocks de novo purine biosynthesis and causes the intermediate AICAR to accumulate more than 20-fold above baseline. AICAR is a direct AMP mimetic that phosphorylates AMPK-alpha at Thr172, activating the master cellular energy sensor. Notably this activation occurs without a drop in cellular ATP, distinguishing MOTS-c from classical energy-depletion AMPK activation. The pathway is reversible by exogenous folate supplementation in cell culture, confirming folate-cycle inhibition as the upstream target.

  2. 02

    GLUT4 translocation and glucose uptake

    Downstream of AMPK activation, MOTS-c promotes GLUT4 glucose-transporter translocation to the plasma membrane in skeletal muscle (Lee 2015), increasing cellular glucose uptake. In mouse high-fat-diet and age-dependent insulin-resistance models, MOTS-c administration restored whole-body glucose tolerance and insulin sensitivity on clamp testing. Muscle is the primary target tissue; effects in adipose and liver are secondary.

  3. 03

    Stress-responsive nuclear translocation

    Kim 2018 (Cell Metab 28:516-524) showed that under metabolic stress (glucose restriction, oxidative stress, exercise) MOTS-c translocates from cytoplasm to nucleus, where it binds chromatin and modulates expression of genes involved in AMPK signaling, glycolysis, proteostasis, and stress response. Gene-set enrichment pointed to antioxidant-response-element (ARE) programs and NRF2 targets. This gives MOTS-c a dual-compartment mechanism: a cytoplasmic metabolic-enzyme arm (folate-AICAR-AMPK) and a nuclear transcriptional arm activated specifically by stress.

  4. 04

    Exercise mimetic and muscle-adaptation signaling

    Reynolds 2021 (Nat Commun 12:470) measured endogenous MOTS-c in human subjects before and after exercise: muscle-tissue MOTS-c rose approximately 12-fold immediately post-exercise and remained partially elevated for hours, with plasma MOTS-c rising about 50%. In aged mice, late-life intermittent MOTS-c injection (three times weekly starting at 23.5 months) improved grip strength, balance, and treadmill endurance — aged treated animals roughly doubled their running time. The paper framed MOTS-c as a 'bona fide exercise mimetic' activating the same AMPK-downstream adaptive programs as exercise itself.

  5. 05

    NAD+/SIRT1 axis and mitochondrial biogenesis

    MOTS-c treatment raises intracellular NAD+ and activates SIRT1-dependent deacetylation of PGC-1α and related metabolic transcription factors, driving mitochondrial biogenesis (Lee 2015; Kim 2018). The SIRT1 dependency was shown by loss-of-function in cell models where SIRT1 knockdown blunted MOTS-c's glycolytic effect. This positions MOTS-c on the same longevity-pathway map as caloric restriction, metformin, and NAD+ precursors.

  6. 06

    AMPK-HIF-1α-PFKFB3 in non-metabolic tissue (newer, single-lab)

    A 2025 paper in the American Journal of Respiratory Cell and Molecular Biology reported that MOTS-c protects pulmonary vascular endothelial cells from cardiopulmonary-bypass-induced injury via AMPK-HIF-1α-PFKFB3-mediated glycolytic reprogramming. This is a single-lab preclinical finding and the first mechanistic extension of MOTS-c beyond classical metabolic tissues; it should not be treated as established until replicated.

  7. 07

    What is NOT known about the mechanism

    No cell-surface receptor for MOTS-c has been identified. Cellular uptake, tissue distribution, and intracellular trafficking (particularly the mechanism of nuclear translocation under stress) are only partially characterized. Human pharmacokinetics of exogenous synthetic MOTS-c — plasma half-life, bioavailability by route, metabolism, elimination — are absent from peer-reviewed literature. The relationship between endogenous MOTS-c and exogenous pharmacological dosing is not worked out; physiological concentrations are in the low-ng/mL range and therapeutic-dose targets in animal studies are orders of magnitude above this.

§ Investigated uses

What it’s
been studied for.

Investigated does not mean proven. This list shows every use that appears in the published literature, regardless of evidence strength. See the grade matrix above for which ones have actually held up.

  • Prevention of high-fat-diet and age-dependent insulin resistance

    Lee 2015 Cell Metabolism — mouse models only

  • Exercise-mimetic effect on physical performance in aged mice

    Reynolds 2021 Nature Communications — late-life mouse dosing; human arm is exercise-induction measurement only

  • Anti-obesity / diet-induced weight-gain attenuation

    Lee 2015, Reynolds 2021 — mouse; no human weight-loss trial

  • Type 2 diabetes biomarker

    Du 2018 Diab Res Clin Pract, Ramanjaneya 2019 JCEM — observational human cohorts; lower circulating MOTS-c in T2D and insulin-resistant subjects

  • Healthspan extension in aged rodents

    Reynolds 2021 — late-life dosing with trend-level median/max lifespan extension, underpowered for survival

  • Cardiopulmonary-bypass-induced acute lung injury

    Single 2025 AJRCMB preclinical study — not replicated

  • Ocular / retinal disease (age-related macular degeneration models)

    Cell-culture and preclinical only (Yin 2023 IJMS review)

  • Population-genetics signal for human longevity

    m.1382A>C variant enriched in long-lived Japanese cohorts (Fuku 2015, Zempo 2016) — association, not causal proof

§ The honest gaps

What we don’t
know yet.

Every peptide page on this site is required to include this section. Absence of evidence is information. If we don’t flag the gaps, we’re lying by omission.

  • !

    No interventional trial of exogenous synthetic MOTS-c in humans has been published or registered on ClinicalTrials.gov as of 2026-04-20. Every human number on this page is either observational (plasma MOTS-c biomarker cohorts) or an exercise-induction measurement of endogenous MOTS-c — not a response to drug dosing.

  • !

    Human pharmacokinetics are unknown. No peer-reviewed data exists on plasma half-life, volume of distribution, tissue penetration, or route-dependent bioavailability for synthetic MOTS-c in humans. Animal data is sparse.

  • !

    No cell-surface receptor has been identified, which limits structure-activity work, dose prediction, and mechanistic understanding of why the peptide works at pharmacologic doses orders of magnitude above endogenous plasma concentrations.

  • !

    The mouse lifespan finding in Reynolds 2021 (~6% median, ~7% maximum extension) is underpowered for survival statistics and has not been replicated by an independent lab.

  • !

    Translation from rodent skeletal muscle to human skeletal muscle is unvalidated. The exercise-induction data in humans shows the pathway is active, but exogenous dosing has never been tested.

  • !

    Long-term human safety is entirely uncharacterized. Repeated-dose immunogenicity (anti-drug antibody formation) has not been studied.

  • !

    The question of whether chronic AMPK activation via MOTS-c is beneficial or harmful across tissues is unresolved. AMPK activation is context-dependent and has been associated with both pro-survival and pro-catabolic effects.

  • !

    Interactions with metformin, GLP-1 agonists, and other AMPK-adjacent or insulin-sensitizing agents are unstudied.

§ On YouTube

What experts and
influencers say.

We index YouTube content discussing MOTS-cand tag every speaker by credential and trust level. The goal is not to summarize the internet — it’s to tell you which voices to weight.

  • MOTS-c and the Mitochondrial-Derived Peptide Family — Changhan Lee

    Buck Institute / Aging Research Seminars·PhD, Associate Professor, USC Leonard Davis School of Gerontology; lead author on Lee 2015 and senior author on Reynolds 2021

    The discoverer walks through the folate-AICAR-AMPK mechanism and the exercise-mimetic framing, and is explicit that every human number so far is observational or endogenous — no interventional human trial has been run.

    Verified credentials

  • MOTS-c: Exercise in a Peptide? What the Aging Evidence Really Says

    Peter Attia MD·MD; longevity-medicine physician

    Attia walks through Reynolds 2021 in detail and flags the central translation question: mouse late-life dosing is striking, but the effect size in humans at any achievable dose is unknown.

    Verified credentials

  • I Tried MOTS-c for 12 Weeks — Here Are My Labs

    Anonymous biohacker·Unverified

    Self-experiment with no control, no blinding, no dose verification, and no independent assay of the compound. Do not weight against published preclinical or observational literature.

    Caution — anecdotal

§ Citations

Every claim,
linked to source.

All 13 sources informing this page, with DOI or PubMed identifiers. Click through to the primary literature.

  1. [01]

    The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

    Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. · Cell Metabolism · 2015

    AnimalPMID 25738459
  2. [02]

    MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

    Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. · Nature Communications · 2021

    AnimalPMID 33479211
  3. [03]

    MOTS-c: an equal-opportunity insulin sensitizer

    Kim SJ, Xiao J, Wan J, Cohen P, Yen K · Cell Metabolism · 2018

    AnimalPMID 30100196
  4. [04]

    Lower circulating MOTS-c levels are associated with the prevalence of insulin resistance in newly diagnosed type 2 diabetes

    Du C, Zhang C, Wu W, Liang Y, Wang A, Wu S, et al. · Diabetes Research and Clinical Practice · 2018

    CohortPMID 29287604
  5. [05]

    Association of circulating MOTS-c levels with obesity-related parameters in a UK cohort

    Ramanjaneya M, Bettahi I, Jerobin J, Chandra P, Abi Khalil C, Skarulis M, et al. · J Clin Endocrinol Metab · 2019

    CohortPMID 31276177
  6. [06]

    The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?

    Fuku N, Pareja-Galeano H, Zempo H, Alis R, Arai Y, Lucia A, Miyachi M · Aging Cell · 2015

    CohortPMID 26670459
  7. [07]

    Association between the MOTS-c variant m.1382A>C and physical performance in a Japanese cohort

    Zempo H, Kim SJ, Fuku N, Nishida Y, Higaki Y, Wakabayashi H, et al. · Aging · 2016

    CohortPMID 27453537
  8. [08]

    MOTS-c, the most recent mitochondrial derived peptide in human aging and age-related diseases

    Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC · International Journal of Molecular Sciences · 2022

    Systematic reviewPMID 36232431
  9. [09]

    Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging

    Wan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J · Journal of Translational Medicine · 2023

    Systematic reviewPMID 36707817
  10. [10]

    MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation

    Merry TL, Chan A, Woodhead JST, Reynolds JC, Kumagai H, Kim SJ, Lee C · Frontiers in Endocrinology · 2023

    Systematic reviewPMID 36768720
  11. [11]

    A mighty mitochondrial microprotein: the protective role of MOTS-c in acute lung injury

    Editorial · American Journal of Respiratory Cell and Molecular Biology · 2025

    AnimalDOI
  12. [12]

    WADA 2026 Prohibited List (in force January 1, 2026) — Section S0 Non-Approved Substances and S4 Hormone and Metabolic Modulators

    World Anti-Doping Agency · WADA · 2026

    RegulatoryLink
  13. [13]

    ClinicalTrials.gov search for MOTS-c (no interventional trials registered as of 2026-04-20)

    U.S. National Library of Medicine · ClinicalTrials.gov · 2026

    RegistrationTrial

§ Adjacent peptides

Worth reading
alongside this.

Compare

SS-31 (Elamipretide)

Mitochondrial-targeted peptide with a different mechanism (cardiolipin binding and cristae stabilization) but the same high-level story: strong preclinical mitochondrial-function data with limited mid-stage human translation. The closest mechanistic peer on the Peptigrade roadmap.

Read its grades

Compare

Epitalon

Longevity/anti-aging peptide with a very different evidence base — almost entirely single-lab Russian geroprotection literature. Shares the longevity framing but not the mechanistic depth or Cell Metabolism-tier publications MOTS-c has.

Read its grades

Compare

IGF-1

The classical endogenous anabolic signal. MOTS-c's skeletal-muscle and glucose-uptake effects overlap IGF-1/insulin pathway territory, and the two are often discussed together in muscle-aging literature even though their upstream biology is unrelated.

Read its grades

Where to research further

Looking for MOTS-c
for laboratory research?

Peptigrade does not sell peptides. RiboCore is one supplier we track that publishes batch-level certificates of analysis (mass spec, HPLC purity) for research-grade material. We have no commercial relationship with them — listing here is editorial.

For research use only · Not for human consumption · Verify legality in your jurisdiction

View at RiboCoreHow we evaluate suppliers →